Retropharmacology of Gliptins: A Focus on Inflammatory Bowel Disease

Authors

  • Srikanta Chandra
  • Avik Das
  • Jyotirmay Samanta
  • Tathagata Ray
  • Lucky Mukherjee
  • Bijayan Mukherjee

Abstract

As we know inflammatory bowel disease is an emergent plight in developed & developing countries. IBD is an idiopathic ulceroinflammatory condition of the bowel which may or may not have transmural stretch. IBD has two clinic pathological condition Ulcerative colitis & Crohns’s disease. In United State of America there are 1.4 million of people suffering from Ulcerative colitis. IBD has a plethora of comorbid disorders .Gastrointestinal disorder arising from cholelithiasis, cutaneous disease arising from psoriasis & metabolic disorders arising from diabetes mellitus. DPP4 which is instrumental in aggravating diabetes mellitus gets hiked in IBD too , which may have serious implications in the worsening of the latter in diabetes . Hence, in our research we probed for the anticolitic potential of a standard inhibitor of DPP4, Linagliptin to ensure the enzymes suitability as a probable target for IBD.

Keywords: IBD: Inflammatory Bowel Disease, UC: Ulcerative colitis, CD: Crohn’s disease

DOI

https://doi.org/10.22270/jddt.v9i3-s.2933

Published

2019-06-15
Statistics
Abstract Display: 821
PDF Downloads: 665

How to Cite

1.
Chandra S, Das A, Samanta J, Ray T, Mukherjee L, Mukherjee B. Retropharmacology of Gliptins: A Focus on Inflammatory Bowel Disease. J. Drug Delivery Ther. [Internet]. 2019 Jun. 15 [cited 2026 Jan. 28];9(3-s):1013-8. Available from: https://jddtonline.info/index.php/jddt/article/view/2933

How to Cite

1.
Chandra S, Das A, Samanta J, Ray T, Mukherjee L, Mukherjee B. Retropharmacology of Gliptins: A Focus on Inflammatory Bowel Disease. J. Drug Delivery Ther. [Internet]. 2019 Jun. 15 [cited 2026 Jan. 28];9(3-s):1013-8. Available from: https://jddtonline.info/index.php/jddt/article/view/2933